GO:0072378 blood coagulation, fibrin clot formation: Protein Activation Cascade, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072378 describes the protein activation cascade that leads to a fibrin clot at the site of blood vessel injury, including both positive and negative regulatory events.
• Fibrin clot formation is the final common pathway of coagulation, where thrombin converts fibrinogen to fibrin monomers that polymerize into a stable clot.
• The process is tightly regulated by fibrinolysis and anticoagulant pathways to prevent thrombosis or bleeding.
• Dysregulation of fibrin clot formation contributes to thrombotic disorders, coagulopathies, and inflammatory conditions such as COVID-19.
• Key genes include FGA, FGB, FGG, F2, F10, F11, F13A1, PLG, and SERPINC1, among others.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of these genes in clot formation.
Description
Blood coagulation, fibrin clot formation (GO:0072378) is a biological process defined as a protein activation cascade that contributes to blood coagulation and consists of the cascade of enzymatic reactions initiated by physical damage to the wall of a blood vessel, leading to the formation of a fibrin clot at the site of the injury, and includes numerous positive and negative regulatory events. This process is essential for hemostasis, preventing excessive blood loss after vascular injury while maintaining blood fluidity under normal conditions. The cascade involves sequential activation of serine proteases and cofactors, culminating in thrombin-mediated conversion of fibrinogen to fibrin, which polymerizes into a insoluble clot. Researchers study GO:0072378 to understand the molecular basis of bleeding and thrombotic disorders, to identify therapeutic targets, and to develop diagnostic tools. The process is also implicated in inflammation, wound healing, and pathological conditions such as disseminated intravascular coagulation and COVID-19-associated coagulopathy. Advances in CRISPR gene editing and high-throughput screening now allow precise interrogation of genes involved in fibrin clot formation, accelerating translational research.
blood coagulation, fibrin clot formation At A Glance
| GO ID | GO:0072378 |
|---|---|
| GO term | blood coagulation, fibrin clot formation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Formation of a fibrin clot at sites of vascular injury via a protein activation cascade |
| Definition | A protein activation cascade that contributes to blood coagulation and consists of the cascade of enzymatic reactions initiated by physical damage to the wall of a blood vessel, leading to the formation of a fibrin clot at the site of the injury. The process also includes numerous positive and negative regulatory events. |
| Related processes | Platelet activation, fibrinolysis, inflammation, wound healing |
| Key enzymes | Thrombin (F2), Factor Xa (F10), Factor XIa (F11), Factor XIIIa (F13A1) |
| Key substrates | Fibrinogen (FGA, FGB, FGG), Plasminogen (PLG) |
What Is GO:0072378?
GO:0072378, blood coagulation, fibrin clot formation, is the series of enzymatic reactions triggered by physical damage to a blood vessel wall that ultimately produces a fibrin clot at the injury site. It is a protein activation cascade that includes both procoagulant and anticoagulant regulatory events, ensuring localized clot formation. The process begins with exposure of tissue factor and activation of the extrinsic and intrinsic pathways, leading to thrombin generation and fibrin polymerization.
Why Is blood coagulation, fibrin clot formation Important in Cell Biology?
Understanding GO:0072378 is critical because dysregulation of fibrin clot formation underlies major human diseases, including thrombosis, hemorrhage, and coagulopathies associated with infection and inflammation. The process is also a target for anticoagulant and procoagulant therapies, and its components serve as biomarkers for disease risk and progression.
• Central to hemostasis and prevention of blood loss after injury.
• Dysregulation leads to thrombotic disorders such as deep vein thrombosis and pulmonary embolism.
• Implicated in bleeding disorders like hemophilia and fibrinogen deficiencies.
• Contributes to inflammation and coagulopathy in COVID-19.
• Fibrin clot structure influences fibrinolysis and cardiovascular risk.
• Provides targets for anticoagulant drugs (e.g., thrombin inhibitors).
• Involved in wound healing and tissue repair.
• Genetic variants in fibrinogen genes affect clot properties and disease susceptibility.
• CRISPR models enable functional validation of coagulation genes.
• Bioinformatics and screening identify novel regulators of clot formation.
What Happens During blood coagulation, fibrin clot formation?
Initiation of Coagulation
In simple terms: When a blood vessel is injured, the body starts a chain reaction to form a clot.
Coagulation is initiated by physical damage to the vessel wall, exposing tissue factor (TF) to circulating factor VIIa, which activates factor X and IX, leading to initial thrombin generation. This extrinsic pathway is rapidly amplified by the intrinsic pathway, involving factors XI, IX, VIII, and X, resulting in a burst of thrombin production.
Thrombin Generation and Fibrinogen Cleavage
In simple terms: Thrombin acts like molecular scissors, cutting fibrinogen into fibrin pieces that stick together.
Thrombin (factor IIa) cleaves fibrinogen (composed of Aα, Bβ, and γ chains encoded by FGA, FGB, and FGG) to release fibrinopeptides A and B, converting fibrinogen to fibrin monomers. These monomers spontaneously polymerize into protofibrils and then thicker fibers, forming the structural basis of the clot.
Fibrin Stabilization by Factor XIIIa
In simple terms: The clot is strengthened by cross-linking, like adding stitches to hold the fibers together.
Thrombin also activates factor XIII (FXIII) to FXIIIa, a transglutaminase that covalently cross-links fibrin γ and α chains, increasing clot mechanical stability and resistance to fibrinolysis. FXIIIa also cross-links antifibrinolytic proteins such as α2-antiplasmin to fibrin, further stabilizing the clot.
Regulation and Fibrinolysis
In simple terms: The clot is kept in check and eventually dissolved by a balanced system of activators and inhibitors.
Clot formation is regulated by anticoagulant pathways, including antithrombin (SERPINC1), protein C, and tissue factor pathway inhibitor, which limit excessive thrombin generation. Fibrinolysis, mediated by plasminogen activation to plasmin, degrades fibrin and dissolves the clot, a process controlled by activators (tPA, uPA) and inhibitors (PAI-1, α2-antiplasmin). Imbalances in these regulatory events contribute to thrombosis or bleeding.
Key Genes Involved in GO:0072378 blood coagulation, fibrin clot formation
The following genes encode key proteins involved in blood coagulation, fibrin clot formation (GO:0072378).
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGA | Fibrinogen alpha chain; substrate for thrombin | Mutations cause afibrinogenemia/dysfibrinogenemia; target for clot structure studies |
| FGB | Fibrinogen beta chain; substrate for thrombin | Variants affect fibrin polymerization and clot stability |
| FGG | Fibrinogen gamma chain; substrate for thrombin | Alternative splicing yields γ' variant with altered clot properties |
| F2 | Prothrombin; precursor of thrombin | Mutations cause prothrombin deficiency or thrombosis; drug target |
| F10 | Factor X; activates prothrombin | Deficiency causes bleeding; target of direct oral anticoagulants |
| F11 | Factor XI; amplifies intrinsic pathway | Deficiency causes hemophilia C; target for antithrombotic therapy |
| F13A1 | Factor XIII A subunit; cross-links fibrin | Deficiency causes delayed bleeding; polymorphisms affect clot stability |
| PLG | Plasminogen; precursor of plasmin | Deficiency causes thrombosis; key for fibrinolysis |
| SERPINC1 | Antithrombin; inhibits thrombin and factor Xa | Deficiency causes thrombophilia; target for heparin therapy |
| PROC | Protein C; anticoagulant | Deficiency causes purpura fulminans and thrombosis |
| PROS1 | Protein S; cofactor for protein C | Deficiency increases thrombosis risk |
| F7 | Factor VII; initiates extrinsic pathway | Deficiency causes bleeding; recombinant FVIIa used therapeutically |
| F8 | Factor VIII; cofactor for factor IXa | Deficiency causes hemophilia A; target for gene therapy |
| F9 | Factor IX; activates factor X | Deficiency causes hemophilia B; target for gene editing |
| VWF | von Willebrand factor; platelet adhesion and FVIII carrier | Deficiency causes von Willebrand disease; involved in thrombosis |
| SERPINE1 | PAI-1; inhibits tPA and uPA | Elevated levels associated with thrombosis; regulator of fibrinolysis |
| PLAT | tPA; activates plasminogen | Used as thrombolytic; deficiency causes impaired fibrinolysis |
| PLAU | uPA; activates plasminogen | Involved in tissue remodeling and fibrinolysis |
How Is blood coagulation, fibrin clot formation Regulated?
The process of blood coagulation, fibrin clot formation is regulated by a balance of procoagulant and anticoagulant mechanisms. Positive feedback loops involving thrombin activate factors V, VIII, and XI, amplifying the cascade. Negative regulation is mediated by antithrombin, protein C pathway, and tissue factor pathway inhibitor, which limit clot propagation. Fibrinolysis provides a counter-regulatory mechanism to dissolve clots, controlled by plasminogen activators and inhibitors. Additionally, clot formation is influenced by local blood flow, platelet activation, and inflammatory mediators.
blood coagulation, fibrin clot formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGA | Afibrinogenemia, dysfibrinogenemia, thrombosis | Knockout or point-mutation in cell lines (e.g., HepG2) |
| F2 | Prothrombin deficiency, thrombosis | Knock-in of prothrombin mutations in iPSC-derived hepatocytes |
| F13A1 | Factor XIII deficiency, impaired wound healing | Knockout in fibroblasts or endothelial cells |
| SERPINC1 | Antithrombin deficiency, thrombophilia | Overexpression or knockout in liver cell models |
| PLG | Plasminogen deficiency, thrombosis | Knockout in hepatocytes or plasma-based assays |
Thrombotic Disorders
Excessive or dysregulated fibrin clot formation contributes to arterial and venous thrombosis, including myocardial infarction, stroke, and deep vein thrombosis. Genetic variants in fibrinogen genes (FGA, FGB, FGG) and prothrombotic mutations (e.g., factor V Leiden) alter clot structure and stability, increasing thrombosis risk. Antithrombin, protein C, and protein S deficiencies further predispose to thrombosis.
Bleeding Disorders
Deficiencies or dysfunction of coagulation factors (e.g., F8, F9, F11, F13A1) or fibrinogen lead to bleeding disorders such as hemophilia A/B, factor XI deficiency, and afibrinogenemia. These conditions are characterized by impaired fibrin clot formation and delayed wound healing.
Coagulopathy in COVID-19
COVID-19 is associated with a high incidence of thrombotic complications and coagulopathy, characterized by elevated D-dimer, fibrinogen, and prothrombotic microparticles. The inflammatory milieu and endothelial injury promote fibrin clot formation, contributing to organ damage.
Cancer-Associated Thrombosis
Malignancies often induce a hypercoagulable state, with tumor cells expressing tissue factor and releasing procoagulant microparticles, leading to fibrin clot formation that supports tumor progression and metastasis. Targeting coagulation pathways is an area of active research.
From blood coagulation, fibrin clot formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FGA impair fibrin clot formation? | FGA knockout in HepG2 or iPSC-derived hepatocytes |
| How does a specific FGB mutation affect fibrin polymerization? | Point mutation knock-in in cell lines |
| Can overexpression of SERPINC1 reduce thrombin generation? | Overexpression in liver cell lines |
| What is the role of F13A1 in clot stability? | Knockout or tagged knock-in in fibroblasts |
| Does a F2 variant alter thrombin activity? | Knock-in of variant in hepatocyte-like cells |
| Can CRISPR library screening identify novel regulators of fibrin clot formation? | Genome-wide knockout library in a suitable cell model |
How to Study the blood coagulation, fibrin clot formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Turbidity assay | Fibrin polymerization kinetics | Assessing clot formation in plasma or purified fibrinogen |
| Thromboelastography | Viscoelastic properties of clot | Global hemostasis in clinical samples |
| Mass spectrometry | Fibrinopeptide release, cross-links | Structural characterization of fibrin |
| CRISPR knockout screening | Gene essentiality for clot formation | Discovery of novel regulators |
| RNA-seq | Transcriptional changes in coagulation genes | Response to genetic or pharmacological perturbation |
| Proteomics | Protein abundance and modifications | Identifying biomarkers and pathways |
| Confocal microscopy | Fibrin network architecture | Visualizing clot structure |
| Bioinformatics pathway analysis | Enrichment of coagulation pathways | Interpreting omics data |
Clot Formation Assays
Turbidity, thromboelastography, and fibrin polymerization assays measure clot formation kinetics and structure using plasma or purified fibrinogen. These methods are essential to quantify the impact of genetic modifications on fibrin clot formation.
Proteomics and Mass Spectrometry
Proteomic approaches identify post-translational modifications and interacting partners of coagulation factors, revealing regulatory mechanisms. Mass spectrometry can detect fibrinopeptide release and cross-linking sites.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout or activation screens coupled with next-generation sequencing enable unbiased discovery of genes regulating fibrin clot formation. Bioinformatics pipelines analyze screening data to identify candidate regulators and pathways.
Imaging and Microscopy
Fluorescence and electron microscopy visualize fibrin fiber networks and clot architecture at high resolution, providing insights into structural abnormalities caused by gene variants.
How CRISPR Can Be Used to Study GO:0072378 blood coagulation, fibrin clot formation
Knockout
CRISPR knockout of genes such as FGA, FGB, or FGG in hepatocyte cell lines abolishes fibrinogen production, providing a clean background to study clot formation defects and rescue with wild-type or mutant constructs.
Point Mutation
Introducing disease-associated point mutations (e.g., in F2 or F13A1) via CRISPR base editing or homology-directed repair allows precise modeling of altered protein function and its impact on fibrin clot formation.
Knock-in
Knock-in of tagged or reporter genes (e.g., GFP-FGA) enables real-time tracking of fibrinogen secretion and incorporation into clots, facilitating mechanistic studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of anticoagulant genes like SERPINC1 or PROC can be used to test their capacity to suppress thrombin generation and fibrin clot formation.
How EDITGENE Supports blood coagulation, fibrin clot formation Research
Researchers studying blood coagulation, fibrin clot formation-related genes often need to determine whether a candidate gene is causally involved in the process, and CRISPR-based models provide a robust way to establish causality. EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for blood coagulation, fibrin clot formation research.
Frequently Asked Questions About blood coagulation, fibrin clot formation
What is GO:0072378?
GO:0072378 is the Gene Ontology term for blood coagulation, fibrin clot formation, a biological process describing the protein activation cascade that leads to a fibrin clot at sites of vascular injury.
What genes are involved in blood coagulation, fibrin clot formation?
Key genes include FGA, FGB, FGG, F2, F10, F11, F13A1, PLG, SERPINC1, PROC, and PROS1, among others.
How does fibrin clot formation occur?
It is initiated by vessel injury, followed by activation of coagulation factors, thrombin generation, cleavage of fibrinogen to fibrin, and stabilization by factor XIIIa.
What is the role of thrombin in fibrin clot formation?
Thrombin converts fibrinogen to fibrin monomers and activates factor XIII, which cross-links fibrin to stabilize the clot.
What diseases are associated with defects in fibrin clot formation?
Thrombosis, bleeding disorders, hemophilia, afibrinogenemia, and COVID-19-associated coagulopathy.
How is fibrin clot formation regulated?
It is regulated by anticoagulant pathways (antithrombin, protein C) and fibrinolysis (plasminogen activators and inhibitors).
What methods are used to study fibrin clot formation?
Turbidity assays, thromboelastography, mass spectrometry, CRISPR screening, and imaging.
Can CRISPR be used to study genes in fibrin clot formation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of coagulation genes.
What is the difference between fibrin clot formation and fibrinolysis?
Fibrin clot formation builds the clot, while fibrinolysis dissolves it; both are tightly balanced.
Why is fibrin clot formation important in COVID-19?
COVID-19 induces a hypercoagulable state with increased fibrin clot formation, contributing to thrombotic complications.
Conclusion
GO:0072378, blood coagulation, fibrin clot formation, is a fundamental biological process that ensures hemostasis and is implicated in a wide range of diseases. Understanding its molecular players and regulatory mechanisms is essential for developing targeted therapies. CRISPR-based models and advanced screening technologies offer powerful tools to dissect this cascade and identify novel therapeutic targets.
References
- 1. Chapin JC et al.. 2015. Fibrinolysis and the control of blood coagulation.. Blood Rev 29(1):17-24 PMID: 25294122
- 2. Norris LA. 2003. Blood coagulation.. Best Pract Res Clin Obstet Gynaecol 17(3):369-83 PMID: 12787532
- 3. Litvinov RI et al.. 2021. Fibrinogen and Fibrin.. Subcell Biochem 96:471-501 PMID: 33252741
- 4. Iba T et al.. 2020. Coagulopathy in COVID-19.. J Thromb Haemost 18(9):2103-2109 PMID: 32558075
- 5. Risman RA et al.. 2025. Deconstructing fibrin(ogen) structure.. J Thromb Haemost 23(2):368-380 PMID: 39536819
- 6. Ząbczyk M et al.. 2024. Novel factors affecting fibrin clot formation and their clinical implications.. Pol Arch Intern Med 134(12) PMID: 39503573
- 7. Ms M et al.. 2024. Modulating Coagulation via Bioinspired Mesoporous Calcium-Decorated Silica Nanoparticles for Efficient Fibrin Clot Formation.. ACS Appl Bio Mater 7(10):6998-7008 PMID: 39307996
- 8. Sidelmann JJ et al.. 2000. Fibrin clot formation and lysis: basic mechanisms.. Semin Thromb Hemost 26(6):605-18 PMID: 11140797
